TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30350134

Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Full mouth probing pocket depth (PPD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Periodontitis (overall)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No periodontitis
Number of subjects: 103
Study: 30350179

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) 35 mg/m² during a 28-day treatment cycle
Number of subjects: 549
Study: 30351341

Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor luminespib (AUY922)
Number of subjects: 29
Study: 30351349

Group type: EXPERIMENTAL
Intervention: Clinical prediction rule for MRSA transmission to HCWs' gowns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current clinical practice (nares surveillance culture for MRSA colonization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediction rule in validation cohort
Number of subjects: 0
Study: 30351367

Group type: EXPERIMENTAL
Intervention: AHEI diet quality score
Number of subjects: 30904

Group type: EXPERIMENTAL
Intervention: AMED diet quality score
Number of subjects: 30904

Group type: EXPERIMENTAL
Intervention: DASH diet quality score
Number of subjects: 30904

Group type: EXPERIMENTAL
Intervention: Central nervous system GRSs
Number of subjects: 30904

Group type: EXPERIMENTAL
Intervention: Non-central nervous system GRSs
Number of subjects: 30904
Study: 30351381

Group type: EXPERIMENTAL
Intervention: Anemic male infants
Number of subjects: 95

Group type: COMPARATOR
Intervention: IDA subjects (both sexes)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: IDA male infants
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: IDA female infants
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Anemia (both sexes)
Number of subjects: 95
Study: 30351387

Group type: EXPERIMENTAL
Intervention: Exercise training (8 km running every second day for 22 days)
Number of subjects: 10
Study: 30351428

Group type: EXPERIMENTAL
Intervention: Neutral posture during clinical shoulder tests
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Slouched posture during clinical shoulder tests
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Upright posture during clinical shoulder tests
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neutral posture (control group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Slouched posture (control group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Upright posture (control group)
Number of subjects: 70
Study: 30351999

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 24
Study: 30352437

Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (LaC)
Number of subjects: 2026
Study: 30352440

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) on
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cochlear Implant (CI) off
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 18
Study: 30352550

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) with a single fraction of 26Gy for tumours ≤4 cm in maximum diameter.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) with 42Gy in three fractions for tumours >4 cm in maximum diameter.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 70
Study: 30352576

Group type: EXPERIMENTAL
Intervention: HYP-RT with concomitant CDDP (4 weekly cycles of 35 mg/m2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HYP-RT with concomitant CDDP
Number of subjects: 20
Study: 30352608

Group type: EXPERIMENTAL
Intervention: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Concomitant chemo-radiotherapy (reference treatment)
Number of subjects: 21
Study: 30352696

Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function initiation at 3 months
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function initiation at 12 months
Number of subjects: 195
Study: 30352714

Group type: EXPERIMENTAL
Intervention: Postdischarge opioid prescription (median 225mg OMEQ)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Postdischarge opioid use (median 22.5mg OMEQ)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Opioid disposal practices
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Prescribing practices
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Comparison of surgical approaches (open vs robotic)
Number of subjects: 205
Study: 30352912

Group type: EXPERIMENTAL
Intervention: Lateral angulation technique (LAT) targeting the anterior superior iliac spine (ASIS)
Number of subjects: 25
Study: 30352941

Group type: EXPERIMENTAL
Intervention: Dalantercept (0.6 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dalantercept (0.4 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Number of subjects: 21
Study: 30353044

Group type: EXPERIMENTAL
Intervention: Olaparib (Lynparza™) maintenance monotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: No detectable HRR mutations (Control)
Number of subjects: 95
Study: 30353380

Group type: COMPARATOR
Intervention: Nondeprived patients (n=177)
Number of subjects: 1834

Group type: COMPARATOR
Intervention: Deprived patients (n=97)
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Overall cohort (n=1447)
Number of subjects: 1834

Group type: COMPARATOR
Intervention: Nondeprived patients
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Socially deprived patients
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 1834
Study: 30353806

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment for 4 months
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no PAP treatment)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: PAP treatment adherence in participants without obesity
Number of subjects: 198
Study: 30353813

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 92

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 92
Study: 30353817

Group type: EXPERIMENTAL
Intervention: Self-reported WASO in HxCP group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Actigraphic WASO in HxCP group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Depression in HxCP group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-reported WASO and SE in HxCP group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-reported WASO and depression in NCP group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily pain in NCP group
Number of subjects: 60
Study: 30354232

Group type: EXPERIMENTAL
Intervention: Incomplete anterior Circle of Willis (COW)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Unilateral carotid artery stenosis
Number of subjects: 482

Group type: COMPARATOR
Intervention: Other plaque features
Number of subjects: 482
Study: 30354288

Group type: EXPERIMENTAL
Intervention: AI-guided pulmonary vein isolation (PVI) with target values of 550 for anterior and 400 for posterior left atrial regions.
Number of subjects: 40
Study: 30354289

Group type: EXPERIMENTAL
Intervention: Cardio-neuromodulation through a right-sided approach
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cardio-neuromodulation
Number of subjects: 20
Study: 30354460

Group type: EXPERIMENTAL
Intervention: European Society of Cardiology pathway
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: European Society of Cardiology pathway with HEART score ≤3
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: High-STEACS pathway
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: Clinical risk scores with High-STEACS pathway
Number of subjects: 1935
Study: 30354556

Group type: EXPERIMENTAL
Intervention: Interatrial shunt device (IASD)
Number of subjects: 64
Study: 30354576

Group type: COMPARATOR
Intervention: High-income countries
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Upper-middle-income countries
Number of subjects: 7141
Study: 30354592

Group type: EXPERIMENTAL
Intervention: Prehospital DAPT
Number of subjects: 3548

Group type: COMPARATOR
Intervention: In-hospital DAPT
Number of subjects: 3548
Study: 30354595

Group type: EXPERIMENTAL
Intervention: Primary PCI in late-presenting patients (12 to 72 hours after symptom onset)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Primary PCI in early-presenting patients (<12 hours after symptom onset)
Number of subjects: 865
Study: 30354636

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon treatment
Number of subjects: 157
Study: 30354645

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon
Number of subjects: 0
Study: 30354650

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 891

Group type: COMPARATOR
Intervention: Medical treatment (reference group)
Number of subjects: 891
Study: 30354721

Group type: EXPERIMENTAL
Intervention: Preterm group
Number of subjects: 92
Study: 30354737

Group type: EXPERIMENTAL
Intervention: Appropriate secondary prevention treatment at discharge (dual antiplatelet therapy and moderate/high dose statins, new-P2Y12 inhibitors, ACE inhibitors/ARBs, beta-blockers as indicated)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Evidence-based treatments at discharge
Number of subjects: 4169
Study: 30354977

Group type: EXPERIMENTAL
Intervention: Whole-blood miRNA sequencing profiling
Number of subjects: 0
Study: 30354984

Group type: EXPERIMENTAL
Intervention: Iodine sign
Number of subjects: 91

Group type: COMPARATOR
Intervention: Spot sign
Number of subjects: 91
Study: 30355158

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (20 billion CFU) once daily for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vancomycin (250 mg QID for 10 days)
Number of subjects: 20
Study: 30355199

Group type: EXPERIMENTAL
Intervention: Highest oxLDL/HDL quartile
Number of subjects: 3019

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 3019
Study: 30355285

Group type: EXPERIMENTAL
Intervention: Laryngeal mask UNIQUE® (LMAU) in correct position
Number of subjects: 202

Group type: COMPARATOR
Intervention: Laryngeal mask UNIQUE® (LMAU) in radiologically misplaced position
Number of subjects: 202
Study: 30355560

Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for NF
Number of subjects: 55

Group type: COMPARATOR
Intervention: Health Enhancement Program for NF
Number of subjects: 55
Study: 30355563

Group type: EXPERIMENTAL
Intervention: Crush the Crave (CTC)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: On the Road to Quitting (OnRQ)
Number of subjects: 1599
Study: 30355607

Group type: EXPERIMENTAL
Intervention: NODDI (Neurite Orientation Dispersion and Density Imaging)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional DTI (Diffusion Tensor Imaging)
Number of subjects: 0
Study: 30355760

Group type: EXPERIMENTAL
Intervention: AHPV assay
Number of subjects: 10040

Group type: COMPARATOR
Intervention: HC2 test
Number of subjects: 10040

Group type: COMPARATOR
Intervention: LBC test
Number of subjects: 10040
Study: 30355792

Group type: EXPERIMENTAL
Intervention: Brief contact interventions (BCIs) provided to individuals discharged from the hospital after a suicide attempt, including a crisis card with an emergency number and systematic recontact 6 months later.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional 10-day call for individuals whose index suicide attempt is not the first one.
Number of subjects: 0
Study: 30355795

Group type: EXPERIMENTAL
Intervention: Enteral feeding during therapeutic hypothermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous dextrose without any parenteral nutrition (PN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 30345376

Group type: EXPERIMENTAL
Intervention: Ocular signs or symptoms observed throughout the study period
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Evidence of concurrent systemic disease
Number of subjects: 696
Study: 30357273

Group type: EXPERIMENTAL
Intervention: Diagnostic strategy including pretest clinical probability assessment, high-sensitivity D-dimer testing, bilateral lower limb compression ultrasonography (CUS), and computed tomography pulmonary angiography (CTPA)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Untreated women after exclusion of PE based on negative results on the diagnostic work-up
Number of subjects: 395
Study: 30357440

Group type: EXPERIMENTAL
Intervention: First FMT
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Second FMT
Number of subjects: 69
Study: 30357467

Group type: EXPERIMENTAL
Intervention: Civilians
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Combatants
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1725
Study: 30357641

Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms at HIV testing
Number of subjects: 141
Study: 30358145

Group type: EXPERIMENTAL
Intervention: Overfeeding (OF)
Number of subjects: 22
Study: 30358179

Group type: EXPERIMENTAL
Intervention: Increased dose of nelfinavir during the third trimester
Number of subjects: 18
Study: 30358468

Group type: EXPERIMENTAL
Intervention: Genetic testing for USH1 and USH2 mutations
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Genetic testing for USH2 mutations
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eligibility for UshStat® gene therapy
Number of subjects: 28
Study: 30358859

Group type: EXPERIMENTAL
Intervention: Sickle cell trait genetic variant
Number of subjects: 2658

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) based on 60 variants
Number of subjects: 2658

Group type: EXPERIMENTAL
Intervention: Principal component (PC) factors capturing continental ancestry
Number of subjects: 2658
Study: 30359447

Group type: EXPERIMENTAL
Intervention: Oral dose of 2g of azithromycin
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study: 30359809

Group type: EXPERIMENTAL
Intervention: High risk of obstructive sleep apnea (HR-OSA)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Low risk of obstructive sleep apnea (LR-OSA)
Number of subjects: 144
Study: 30359909

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day) - Cohort 1 (C1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day) - Cohort 2 (C2)
Number of subjects: 84
Study: 30360643

Group type: EXPERIMENTAL
Intervention: Caregiver status (HIV-positive)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Low income
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Lower social support
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Lower HIV knowledge
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Worse HIV illness perceptions
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Greater perceived HIV stigma
Number of subjects: 446
Study: 30361140

Group type: EXPERIMENTAL
Intervention: Track intervention (app-based self-monitoring, dietitian counseling, clinician counseling)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 351
Study: 30361153

Group type: EXPERIMENTAL
Intervention: Prior syncope (recurrent syncope)
Number of subjects: 3580

Group type: COMPARATOR
Intervention: First episode of syncope
Number of subjects: 3580
Study: 30361248

Group type: EXPERIMENTAL
Intervention: Supervised community physical activity
Number of subjects: 0
Study: 30361262

Group type: EXPERIMENTAL
Intervention: Venetoclax (400, 800, or 1200 mg daily) combined with decitabine (20 mg/m²)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Venetoclax (400, 800, or 1200 mg daily) combined with azacitidine
Number of subjects: 145
Study: 30361296

Group type: EXPERIMENTAL
Intervention: Dopamine agonists before intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa slow-release formulation after 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control groups (medicated and drug-naive)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dopamine agonist withdrawal syndrome
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric traits
Number of subjects: 50
Study: 30361434

Group type: EXPERIMENTAL
Intervention: Increased regional oxygen extraction fraction ratio in patients with Moyamoya phenomenon
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 35
Study: 30361858

Group type: COMPARATOR
Intervention: PF-06649751 (0.75 mg, 1.5 mg, 3 mg, 6 mg, 9 mg single dose)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PF-06649751 (5 mg, 15 mg, 25 mg once daily for 21 days)
Number of subjects: 63
Study: 30361875

Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine 500 mg PO TID (could be reduced to 500 mg QD) and exemestane 25 mg QD or letrozole 2.5 mg QD
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine combined with aromatase inhibitors
Number of subjects: 44
Study: 30361959

Group type: EXPERIMENTAL
Intervention: Multiple Stent Delivery System (MSDS)
Number of subjects: 0
Study: 30362288

Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) administered alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) with recombinant factor VIII (rFVIII)
Number of subjects: 0
Study: 30362948

Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed at STI clinic (n = 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed by general practitioner (n = 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed by HIV physician (n = 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed at PrEP clinic (n = 5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse reported by patients (n = 10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concomitant STI at the time of HCV diagnosis (n = 4)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Drug use during sex reported (n = 6)
Number of subjects: 10
Study: 30363395

Group type: EXPERIMENTAL
Intervention: HD gene expansion carriers (HDGECs; CAG expansion ≥36)
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Premanifest HD
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Manifest HD
Number of subjects: 1534

Group type: COMPARATOR
Intervention: Controls (genotype-negative first-degree relatives and family controls)
Number of subjects: 1534
Study: 30363894

Group type: EXPERIMENTAL
Intervention: l-tyrosine 1,000 mg (500 mg 2× daily) for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30363900

Group type: EXPERIMENTAL
Intervention: Electrochemical Skin Conductance (ESC) assessment
Number of subjects: 36
Study: 30363954

Group type: EXPERIMENTAL
Intervention: 6 months of aerobic and/or resistance training
Number of subjects: 202

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 202
Study: 30364428

Group type: EXPERIMENTAL
Intervention: VRC01 (40 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VRC01
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30364565

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: N-terminal pro-peptides of collagen I and III, collagen I C-terminal telopeptides (CTx), matrix metalloproteinases (MMP-2 and MMP-9), and a panel of miRNAs (miRNA-21, miRNA-30d, miRNA-122, miRNA-133a, miRNA-210 and miRNA-486)
Number of subjects: 52
Study: 30364785

Group type: EXPERIMENTAL
Intervention: Automated phone reminders (up to 6 reminders)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Automated plus live phone reminders (up to 6 reminders total)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Automated phone reminders (up to 6 reminders) among Spanish-preferring patients (n=106)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Automated plus live phone reminders among Spanish-preferring patients (n=106)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Automated phone reminders (up to 6 reminders) among English-preferring patients (n=279)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Automated plus live phone reminders among English-preferring patients (n=279)
Number of subjects: 427
Study: 30365164

Group type: EXPERIMENTAL
Intervention: MRI surveillance
Number of subjects: 71

Group type: COMPARATOR
Intervention: US surveillance
Number of subjects: 71
Study: 30365251

Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 116

Group type: COMPARATOR
Intervention: TD group
Number of subjects: 116
Study: 30365452

Group type: EXPERIMENTAL
Intervention: TDF/FTC + DRV/r (once daily; 4 pills/day)
Number of subjects: 774

Group type: COMPARATOR
Intervention: RAL + DRV/r (twice daily; 5 pills/day)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Adherence ≥95% over the last 4 days
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Patients with baseline CD4 <200 cells/mm and HIV-1 RNA ≥100,000 copies per milliliter
Number of subjects: 774
Study: 30366567

Group type: EXPERIMENTAL
Intervention: 1% testosterone gel daily for 12 months
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo gel daily for 12 months
Number of subjects: 390
Study: 30366581

Group type: EXPERIMENTAL
Intervention: Screening test panel (clinical evaluation, daytime arterial blood gas (ABG), nocturnal pulse oximetry (SpO2))
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Screening test panel
Number of subjects: 67
Study: 30366585

Group type: EXPERIMENTAL
Intervention: Breezhaler inhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30366774

Group type: EXPERIMENTAL
Intervention: Increased daily portion of fruits and vegetables
Number of subjects: 48

Group type: COMPARATOR
Intervention: High screen time, high saturated fat, high sugar-sweetened beverages, low protein intake
Number of subjects: 48
Study: 30367117

Group type: EXPERIMENTAL
Intervention: ETS+ tumors
Number of subjects: 10608

Group type: EXPERIMENTAL
Intervention: ETS- tumors
Number of subjects: 10608

Group type: EXPERIMENTAL
Intervention: AR-regulated gene expression
Number of subjects: 10608

Group type: EXPERIMENTAL
Intervention: GSEA
Number of subjects: 10608

Group type: EXPERIMENTAL
Intervention: AR ChIP-seq data
Number of subjects: 10608

Group type: EXPERIMENTAL
Intervention: Dysregulation of ETS-dependent AR-target genes
Number of subjects: 10608
Study: 30367670

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (pre-existing co-morbidity)
Number of subjects: 4107